foto

MD PhD M.A. Middelkamp Hup

Position
Medical Specialist
Main activities
Education, Patient care, Research
Specialisation
Dermatology; focus on Pediatric Dermatology, Atopic Dermatitis and Allergic Contact Dermatitis
Focus of research

Atopic Dermatitis (AD)

 

-AD in children: fillagrin mutations, skin barrier biomarkers and immunological biomarkers, related to clinical parameters and phenotype

 

-The role of allergic contact dermatitis in children with and without AD

 

-Fillagrin mutations and clinical outcome of AD

 

-Immunology: T cells subsets, with emphasis on IL-31 producing T cells; Cytokine profiles in transdermal fluid

 

Haemangiomas

 

- treatment of ulcerated hemangiomas

 

 

 

Key publications
  • Szegedi Krisztina, Kremer Andreas E., Kezic Sanja, Teunissen Marcel B. M., Bos Jan D., Luiten Rosalie M., Res Pieter C., Middelkamp-Hup Maritza A. Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin Experimental dermatology 2012;21 (6):431-436 [PubMed]
  • Proudfoot L. E., Powell A. M., Ayis S., Barbarot S., Baselga Torres E., Deleuran M., Fölster-Holst R., Gelmetti C., Hernández-Martin A., Middelkamp-Hup M. A., Oranje A. P., Logan K., Perkins M., Patrizi A., Rovatti G., Schofield O., Spuls P., Svensson A., Vestergaard C., Wahlgren C.-F., Schmitt J., Flohr C. The European treatment of severe atopic eczema in children taskforce (TREAT) survey British journal of dermatology 2013;169 (4):901-909 [PubMed]
  • Szegedi K., Lutter R., Res P. C., Bos J. D., Luiten R. M., Kezic S., Middelkamp-Hup M. A. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin Journal of the European Academy of Dermatology and Venereology 2015;29 (11):2136-2144 [PubMed]
  • Roekevisch E., Leeflang M. M. G., Schram M. E., Campbell L. E., Irwin McLean W. H., Kezic S., Bos J. D., Spuls P. I., Middelkamp-Hup M. A. Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment British journal of dermatology 2017;177 (6):1745-1746 [PubMed]
  • Lubbes Stefanie, Rustemeyer Thomas, Sillevis Smitt Johannes H., Schuttelaar Marie Louise, Middelkamp-Hup Maritza A. Contact sensitization in Dutch children and adolescents with and without atopic dermatitis - a retrospective analysis Contact dermatitis 2017;76 (3):151-159 [PubMed]
All Publications
Research programmes

Prof. PhD R.M. Luiten (Pigment cell disorders of the skin)

Luiten's research team is specialized in the immunopathogenesis and treatment of pigment cell disorders of the skin, including vitiligo and melanoma. Luiten's research has clearly established a positive relation between vitiligo and melanoma regression, by showing that 1) vitiligo patients have a three-fold decreased life-time risk of developing melanoma , 2) vitiligo is an autoimmunity against melanocytes in the skin, leading to loss of skin pigmentation, 3) melanoma patients who develop vitiligo, referred to as melanoma-associated leucoderma or vitiligo (MAL), have immunity reactive with both melanocytes and melanoma cells, 4) the appearance of MAL in melanoma patients is associated with favorable clinical outcome (progression free- and overall survival), and 5) vitiligo-inducing compound monobenzone combined with imiquimod and/or CpG induces anti-melanoma immunity and suppresses melanoma growth in mice and patients. This highlights vitiligo as a favorable sign for melanoma patients and the importance of its mechanism of action for melanoma treatment. The group has developed a new melanoma therapy consisting of monobenzone and immune stimulation (patent granted, preclinical and clinical proof-of-concept obtained). Their investigator-initiated clinical trial at the NKI-AVL shows local clinical responses of skin metastases and successful induction of anti-melanoma immunity in most patients. This therapy is developed further clinically. New projects include biomarker research for response of melanoma patients to immune checkpoint inhibitors, targeting of melanoma cell heterogeneity by vaccination immunotherapy and diagnosis and treatment of lentigo maligna. Vitiligo clinical research aims at improving skin suspension transplantation therapy and the development of  scoring systems for vitiligo disease activity. Biomarkers for the differential diagnosis of vitiligo and melanoma-associated vitiligo are studied, applicable in preventing immunesuppressive therapy in vitiligo patients with an undiagnosed melanoma. Luiten's group joined forces of the NFU expertise center on Pigment Disorders (AMC) with the skin tissue engineering expertise of prof Gibbs (VUMC), to apply this technology in vitiligo and melanoma immunotherapy research. 

 

Faculty
PhD W.J. Bakker
MD PhD M.W. Bekkenk
MD PhD M.A. Middelkamp Hup
MD PhD A. Wolkerstorfer

Postdocs
PhD W. Ouwerkerk

Others
BEng S. Chielie
BEng G. Krebbers
N.O.P. van Uden

Prof. PhD P.I. Spuls (dermato-immunology and dermato-epidemiology)

Psoriasis: biologic antibodyformation, RCT etanercept versus infliximab, methotrexate optimalisation, new developments, compliance, nail psoriasis, maintenance treatment, combination treatment, guideline development,  registries, quality of life, side-effect monitoring

Atopic dermatitis: harmonisation outcome parameters, new treatment options (azathioprine versus methotrexate (short and long term), systemic treatments, registry, fillagrin mutations, biomarkers, diagnostic criteria, topicals, side- effect monitoring, antibody formation dupilumab, skintypes, phenotypering, infections, pregnancy/lactation, astma and atopic dermatitis, 

Rosacea: quality of life, RCT doxycyckine versus minicycline, laser treatment rosacea papulopustulosa

Off-label drug use in dermatology: RCT, guideline, Regieraad project, registry

Methodology: evidence based medicine/dermatology, guideline development, critical appraised topics, core outcome set development

Psychodermatology: ehealth Beter gestemd met de huid, shared decision making, diagnostiek psychosociale problematiek, PROMs

Vascular malformations: OVAMA core outcome set development, diagnostic criteria, PROMs

 

Faculty
MD PhD M.A. Middelkamp Hup
MD M.M.D. van der Linden

Others
G.A.M. Appel
P.B. Eppenga-Franklin
H.M. van der Stok

Prof. PhD J.D. Bos (IMMUNODERMATOLOGY)

Faculty
MA PhD J. de Korte
Prof. MD PhD H.J.C. de Vries
MD PhD J.R. Mekkes
MD PhD M.A. Middelkamp Hup
MD PhD J.H. Sillevis Smitt
MD PhD E.J.M. van Leent

MD PhD M.A. Middelkamp Hup (Promoties)

(Medewerkers buiten research programmes van afdeling Dermatologie)

Faculty
MA PhD J. de Korte
Prof. MD PhD H.J.C. de Vries
MD PhD J.R. Mekkes
MD PhD M.A. Middelkamp Hup
MD PhD J.H. Sillevis Smitt
MD PhD E.J.M. van Leent